CONGRESS GUIDE

ERS International Congress 2016
DETAILED PROGRAMME
TUESDAY 06 SEPTEMBER, 2016
15:15
15:45
Novel aspects of severe asthma from BIOAIR
Sven-Erik Dahlén (Stockholm, Sweden)
Severe asthma in Asia: insight into phenotypes
Tae-Bum Kim (Seoul, Republic of Korea)
4530
4531
16:15
Data integration: the way to personalised treatment in severe asthma
Peter J. Sterk (Amsterdam, Netherlands)
Platinum Room 3+4 Session 647 14:45 - 16:45
Hot topics: Noninvasive ventilation versus high-flow nasal therapy for hypoxemic patients
Aims : To describe the physiological effects of applying NIV or HFNT, its advantages and limitations, and the criteria regarding how and
when apply HFNT.
Tag(s) : Clinical
Target audience : Clinician, Nurse, Physiotherapist, Resident, Thoracic surgeon
Chairs : Cesare Gregoretti (TORINO, TO, Italy), Stylianos Orfanos (Athens, Greece)
4532
14:45
15:15
15:45
The physiological effects of NIV and HFNT: HFNT is not continuous airway pressure
Nicholas S. Hill (Providence, United States of America)
HFNT in acute de novo hypoxiemic patients
Jean-Pierre Frat (Poitiers, France)
High-flow nasal oxygen versus noninvasive positive airway pressure after surgery
François Stephan (Plessis-Le-Robinson, France)
4533
4534
4535
16:15
HFNT or NIV in hypoxiemic patients after extubation in intensive care unit
Salvatore Maggiore (Chieti, Italy)
Room C Session 648 14:45 - 16:45
Oral Presentation: Therapeutic horizons: novel targets and pharmacological models
Chairs : Ross Vlahos (Bundoora, VIC, Australia), Hoeke Baarsma (Munich, Germany)
4536
OA4537
OA4538
OA4539
OA4540
OA4541
OA4542
OA4543
LATE-BREAKING ABSTRACT: MUC1 downregulation induces corticosteroid resistance in asthma’s in vitro and
in vivo models
Anselm Morell (Valencia, Spain), Anselm Morell, Estefania Bel, Javier Milara, Esteban Morcillo, Julio Cortijo
Intratracheal administration of bone marrow-derived mesenchymal stem cells ameliorates lung function
Giuseppe Spaziano (Naples, Italy), Giuseppe Spaziano, Konrad Urbanek, Antonella De Angelis, Elena Piegari, Maria
Matteis, Manuela Sgambato, Gioia Tartaglione, Teresa Palmira Russo, Donato Cappetta, Grazia Esposito, Rosa Russo,
Bruno D’Agostino
Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase
Daniela Miglietta (Parma, Italy), Daniela Miglietta, Chiara Carnini, Veronica Puviani, Harry Finch, Craig Fox, Mary
Fitzgerald, Riccardo Patacchini, Maurizio Civelli, Gino Villetti
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF
Maté Ongenaert (Mechelen, Belgium), Maté Ongenaert, Sonia Dupont, Roland Blanqué, Reginald Brys, Ellen van der Aar,
Bertrand Heckmann
The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated
by TRPM8
Ana Isabel Caceres (Durham, United States of America), Anabel de Caceres Bustos, Boyi Liu, Sairam Jabba, John Morris,
Sven-Eric Jordt
Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug
development and enable inhalational toxico-analysis
Kambez Hajipouran Benam (Cambridge, United States of America), Kambez Hajipouran Benam, Richard Novak, Remi
Villenave, Carolina Lucchesi, Cedric Hubeau, Janna Nawroth, Mariko Hirano-Kobayashi, Thomas C. Ferrante, Youngjae
Choe, Rachelle Prantil-Baun, James C. Weaver, Geraldine A. Hamilton, Anthony Bahinski, Donald E. Ingber
Evaluation of nanoparticles in human lung fibroblasts and PCLS
Anna-Karin Larsson-Callerfelt (Lund, Sweden), Gunilla Westergren-Thorsson, Lena Thiman, Vendela Rissler, Hanna
Karlsson, Anna-Karin Larsson-Callerfelt
297 26.08.2016